FDA 483 - Element Materials Technology Canada Inc. - September 20, 2019

An FDA inspection of Lupin Limited, an API manufacturer in Tarapur, India, revealed significant quality control deficiencies. These included inadequate investigations into metal particle contamination, incomplete batch production records, and improper storage of cleaned equipment and utensils. The findings indicate a need for improved manufacturing practices and adherence to regulatory standards.